同種幹細胞の世界市場規模、シェア、成長分析：タイプ別、用途別、エンドユーザー別、地域別 - 産業予測（2025年～2032年）

世界の同種幹細胞の市場規模は、2023年に2億5,830万米ドルと評価され、2024年の3億2,494万米ドルから2032年には20億3,822万米ドルに成長し、予測期間（2025年～2032年）のCAGRは25.8%で成長する見通しです。

世界の同種幹細胞市場は、慢性疾患や変性疾患の罹患率の増加によって力強い成長を遂げています。健康なドナーから採取された幹細胞は、がん、心血管疾患、自己免疫疾患といった疾患に対する有望な治療ソリューションとなります。「既製の治療法」として機能する幹細胞は、自己由来の治療法に比べて大きな競合優位性を提供し、スケーラブルで利用しやすい細胞治療への関心の高まりは、再生医療への取り組みの急増と一致しています。とはいえ、市場は免疫拒絶反応や移植片対宿主病（GvHD）などの課題に直面しており、患者は免疫不全のリスクにさらされています。さらに、複雑でコストのかかる製造工程、規制上の長いハードル、ドナー細胞の入手可能性に関する倫理的懸念が、市場拡大の大きな障壁となっています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次・一次情報源
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ

同種幹細胞の市場規模：タイプ別、CAGR（2025年～2032年）

• 市場概要
• 間葉系幹細胞（MSC）
• 造血幹細胞（HSC）
• 人工多能性幹細胞（iPSC）
• 胚性幹細胞（ES細胞）

同種幹細胞の市場規模：用途別、CAGR（2025年～2032年）

• 市場概要
• オンコロジー（がん）
• 心血管疾患
• 整形外科疾患
• 神経疾患
• 自己免疫疾患
• 創傷治癒

同種幹細胞の市場規模：エンドユーザー別、CAGR（2025年～2032年）

• 市場概要
• 病院と診療所
• バイオテクノロジーおよび製薬会社
• 学術研究機関

同種幹細胞の市場規模、CAGR（2025年～2032年）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比の比較（2022年～2024年）

主要企業プロファイル

• Mesoblast Limited（Australia）
• Athersys, Inc.（United States）
• Pluristem Therapeutics Inc.（Israel）
• Osiris Therapeutics（United States）
• Gamida Cell（Israel）
• Takeda Pharmaceutical Company Limited（Japan）
• Novartis AG（Switzerland）
• Gilead Sciences, Inc.（Kite Pharma）（United States）
• Bristol Myers Squibb（Juno Therapeutics）（United States）
• Allogene Therapeutics（United States）
• Fate Therapeutics（United States）
• Century Therapeutics（United States）
• Sana Biotechnology（United States）
• Cynata Therapeutics Limited（Australia）
• Lineage Cell Therapeutics, Inc.（United States）

結論と提言

Global Allogeneic Stem Cells Market size was valued at USD 258.3 million in 2023 and is poised to grow from USD 324.94 million in 2024 to USD 2038.22 million by 2032, growing at a CAGR of 25.8% during the forecast period (2025-2032).

The global allogeneic stem cells market is witnessing robust growth, fueled by the increasing incidence of chronic and degenerative diseases. These stem cells, derived from healthy donors, present promising treatment solutions for conditions such as cancer, cardiovascular issues, and autoimmune disorders. Their ability to function as "off-the-shelf therapies" provides a significant competitive edge over autologous treatments, and rising interest in scalable, accessible cell therapies aligns with the surge in regenerative medicine initiatives. Nevertheless, the market faces challenges, including immune rejection and Graft-versus-Host disease (GvHD), which keep patients at risk of immunocompromise. Additionally, the intricate and costly manufacturing processes, along with lengthy regulatory hurdles and ethical concerns regarding donor cell availability, pose substantial barriers to market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Allogeneic Stem Cells market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Allogeneic Stem Cells Market Segments Analysis

Global Allogeneic Stem Cells Market is segmented by Type, Application, End User and region. Based on Type, the market is segmented into Mesenchymal Stem Cells (MSCs), Hematopoietic Stem Cells (HSCs), Induced Pluripotent Stem Cells (iPSCs) and Embryonic Stem Cells (ESCs). Based on Application, the market is segmented into Oncology (Cancer), Cardiovascular Diseases, Orthopaedic Disorders, Neurological Disorders, Autoimmune Diseases and Wound Healing. Based on End User, the market is segmented into Hospitals & Clinics, Biotechnology & Pharmaceutical Companies and Academic & Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Allogeneic Stem Cells Market

The Global Allogeneic Stem Cells market is significantly driven by the advantages of sourcing stem cells from healthy donors, as opposed to autologous therapies which are reliant on individual patients. Allogeneic stem cells are produced in large quantities, leading to immediate availability for treatment. This bulk manufacturing creates a cost-efficient model that promotes widespread access to cutting-edge therapies across various applications and diseases. By offering an off-the-shelf solution, allogeneic stem cells facilitate quicker and easier implementation of innovative treatments, thereby expanding their potential impact in the healthcare market and enhancing patient care opportunities on a broader scale.

Restraints in the Global Allogeneic Stem Cells Market

A significant challenge in the allogeneic stem cell market is the risk of immune rejection by the recipient's body or the donor cells attacking the recipient's tissue, a condition known as Graft-versus-Host Disease (GVHD). This complication often necessitates the use of immunosuppressive medications, which can lead to substantial side effects and potentially diminish the effectiveness of the treatment. Consequently, the need for ongoing management of these adverse effects can hinder patient compliance and overall treatment outcomes, creating a notable restraint on the market for allogeneic stem cell therapies.

Market Trends of the Global Allogeneic Stem Cells Market

The global allogeneic stem cells market is witnessing a significant shift as researchers focus on the development of hypoimmunogenic "stealth" cells, which are designed to evade rejection by the patient's immune system. Leveraging advanced gene-editing technologies, such as CRISPR, these universal donor cells hold the promise of revolutionizing therapeutic approaches by potentially obviating the need for immunosuppressive drugs. This innovation is anticipated to enhance the safety and efficacy of stem cell therapies, thereby attracting greater investment and interest in clinical applications. Consequently, this trend is likely to propel the growth of the allogeneic stem cells market, paving the way for more accessible treatments.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Allogeneic Stem Cells Market Size by Type & CAGR (2025-2032)

• Market Overview
• Mesenchymal Stem Cells (MSCs)
• Hematopoietic Stem Cells (HSCs)
• Induced Pluripotent Stem Cells (iPSCs)
• Embryonic Stem Cells (ESCs)

Global Allogeneic Stem Cells Market Size by Application & CAGR (2025-2032)

• Market Overview
• Oncology (Cancer)
• Cardiovascular Diseases
• Orthopaedic Disorders
• Neurological Disorders
• Autoimmune Diseases
• Wound Healing

Global Allogeneic Stem Cells Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutes

Global Allogeneic Stem Cells Market Size & CAGR (2025-2032)

• North America (Type, Application, End User)
  • US
  • Canada
• Europe (Type, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Mesoblast Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Athersys, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pluristem Therapeutics Inc. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Osiris Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gamida Cell (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (Kite Pharma) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (Juno Therapeutics) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allogene Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fate Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Century Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sana Biotechnology (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cynata Therapeutics Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lineage Cell Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations